Bright Minds Biosciences (DRUG) Retained Earnings (2020 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Retained Earnings data on file, last reported at $5.4 million in Q1 2026.

• Quarterly Retained Earnings rose 148.51% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 148.51% YoY) and the FY2025 annual result came in at $3.9 million, up 32.95% from the prior year.
• Retained Earnings climbed to $5.4 million in Q1 2026, from $4.8 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $5.4 million in Q1 2026 to a low of -$23.5 million in Q3 2023.
• A 5-year average of $1.2 million and a median of $2.2 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings plunged 1337.79% — and 2026, when it soared 148.51%.
• Tracing DRUG's Retained Earnings over 5 years: stood at $2.2 million in 2022, then advanced by 13.9% to $2.5 million in 2023, then retreated by 10.57% to $2.2 million in 2024, then soared by 114.49% to $4.8 million in 2025, then rose by 12.46% to $5.4 million in 2026.
• The last three Retained Earnings figures came in at $5.4 million (Q1 2026), $4.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.